Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.28 Million USD | -73.71% |
| 2022 | -2.46 Million USD | 43.3% |
| 2021 | -4.34 Million USD | -15.74% |
| 2020 | -3.75 Million USD | -80.03% |
| 2019 | -2.08 Million USD | -603.56% |
| 2018 | -296.41 Thousand USD | 6.9% |
| 2017 | -318.38 Thousand USD | 54.3% |
| 2016 | -696.75 Thousand USD | 66.82% |
| 2015 | -2.1 Million USD | -55.92% |
| 2014 | -1.34 Million USD | 24.27% |
| 2013 | -1.77 Million USD | 22.45% |
| 2012 | -2.29 Million USD | 2.76% |
| 2011 | -2.35 Million USD | -600.93% |
| 2010 | -336.47 Thousand USD | -21.76% |
| 2009 | -276.34 Thousand USD | -1036.1% |
| 2008 | -24.32 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -800.32 Thousand USD | 23.52% |
| 2024 Q3 | -392.37 Thousand USD | 40.7% |
| 2024 Q2 | -661.71 Thousand USD | 17.32% |
| 2023 Q2 | -1.41 Million USD | -79.75% |
| 2023 Q3 | -1 Million USD | 29.05% |
| 2023 Q4 | -1.04 Million USD | -4.53% |
| 2023 FY | -4.28 Million USD | -73.71% |
| 2023 Q1 | -785.08 Thousand USD | -18.35% |
| 2022 Q2 | -622.34 Thousand USD | 41.1% |
| 2022 Q1 | -1.05 Million USD | -110.42% |
| 2022 FY | -2.46 Million USD | 43.3% |
| 2022 Q4 | -663.35 Thousand USD | -436.52% |
| 2022 Q3 | -123.64 Thousand USD | 80.13% |
| 2021 Q1 | -1.62 Million USD | -100.34% |
| 2021 Q3 | -475.15 Thousand USD | 47.01% |
| 2021 FY | -4.34 Million USD | -15.74% |
| 2021 Q4 | -502.1 Thousand USD | -5.67% |
| 2021 Q2 | -896.7 Thousand USD | 44.71% |
| 2020 Q3 | -202.04 Thousand USD | 78.24% |
| 2020 FY | -3.75 Million USD | -80.03% |
| 2020 Q2 | -928.59 Thousand USD | -71.81% |
| 2020 Q1 | -540.49 Thousand USD | 18.44% |
| 2020 Q4 | -809.48 Thousand USD | -300.65% |
| 2019 FY | -2.08 Million USD | -603.56% |
| 2019 Q4 | -662.65 Thousand USD | 24.19% |
| 2019 Q2 | -130.29 Thousand USD | 31.93% |
| 2019 Q1 | -191.4 Thousand USD | 22.8% |
| 2019 Q3 | -874.11 Thousand USD | -570.88% |
| 2018 Q2 | -115.72 Thousand USD | -290.77% |
| 2018 Q4 | -247.94 Thousand USD | -421.73% |
| 2018 FY | -296.41 Thousand USD | 6.9% |
| 2018 Q1 | -29.61 Thousand USD | 65.73% |
| 2018 Q3 | -47.52 Thousand USD | 58.93% |
| 2017 Q3 | 48.88 Thousand USD | 118.77% |
| 2017 FY | -318.38 Thousand USD | 54.3% |
| 2017 Q1 | -64.58 Thousand USD | -147.74% |
| 2017 Q4 | -86.41 Thousand USD | -276.77% |
| 2017 Q2 | -260.41 Thousand USD | -303.21% |
| 2016 FY | -696.75 Thousand USD | 66.82% |
| 2016 Q4 | 135.27 Thousand USD | 163.22% |
| 2016 Q1 | -455.04 Thousand USD | -29.52% |
| 2016 Q3 | -213.99 Thousand USD | -31.28% |
| 2016 Q2 | -163 Thousand USD | 64.18% |
| 2015 FY | -2.1 Million USD | -55.92% |
| 2015 Q1 | -39.05 Thousand USD | 83.4% |
| 2015 Q2 | -1.91 Million USD | -4805.66% |
| 2015 Q3 | 206.24 Thousand USD | 110.76% |
| 2015 Q4 | -351.31 Thousand USD | -270.34% |
| 2014 Q2 | -58.15 Thousand USD | -192.63% |
| 2014 Q3 | -1.11 Million USD | -1819.5% |
| 2014 FY | -1.34 Million USD | 24.27% |
| 2014 Q4 | -235.26 Thousand USD | 78.92% |
| 2014 Q1 | 62.78 Thousand USD | -43.79% |
| 2013 Q4 | 111.68 Thousand USD | 140.29% |
| 2013 FY | -1.77 Million USD | 22.45% |
| 2013 Q1 | -974.04 Thousand USD | -44.27% |
| 2013 Q2 | -638.99 Thousand USD | 34.4% |
| 2013 Q3 | -277.18 Thousand USD | 56.62% |
| 2012 Q1 | -23.92 Thousand USD | 98.11% |
| 2012 Q2 | -202.77 Thousand USD | -747.67% |
| 2012 Q4 | -675.16 Thousand USD | -38.54% |
| 2012 Q3 | -487.32 Thousand USD | -140.33% |
| 2012 FY | -2.29 Million USD | 2.76% |
| 2011 Q4 | -1.26 Million USD | -465.43% |
| 2011 FY | -2.35 Million USD | -600.93% |
| 2011 Q2 | -139.38 Thousand USD | 80.82% |
| 2011 Q1 | -726.75 Thousand USD | -1008.45% |
| 2011 Q3 | -224.24 Thousand USD | -60.88% |
| 2010 Q4 | -65.56 Thousand USD | 8.16% |
| 2010 FY | -336.47 Thousand USD | -21.76% |
| 2010 Q2 | -122.49 Thousand USD | -59.78% |
| 2010 Q1 | -76.66 Thousand USD | 45.82% |
| 2010 Q3 | -71.38 Thousand USD | 41.72% |
| 2009 Q4 | -141.51 Thousand USD | -64.99% |
| 2009 Q3 | -85.77 Thousand USD | -135.23% |
| 2009 Q1 | -13.12 Thousand USD | 0.0% |
| 2009 Q2 | -36.46 Thousand USD | -177.89% |
| 2009 FY | -276.34 Thousand USD | -1036.1% |
| 2008 FY | -24.32 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -220.496% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 38.707% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 108.079% |
| Nascent Biotech, Inc. | -2.08 Million USD | -105.012% |
| Rebus Holdings, Inc. | -1.02 Million USD | -319.608% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.571% |
| Qrons Inc. | -789.34 Thousand USD | -442.221% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -576.78% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 93.163% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -930.137% |
| Skye Bioscience, Inc. | -37.64 Million USD | 88.631% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.291% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 34.916% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1465.461% |
| SQZ Biotechnologies Company | -79.46 Million USD | 94.614% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -47.974% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -135.097% |
| Mesoblast Limited | -87.95 Million USD | 95.134% |
| Marizyme, Inc. | -65.34 Million USD | 93.45% |
| Genus plc | 7.9 Million USD | 154.177% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 60.704% |
| Pharming Group N.V. | -10.54 Million USD | 59.424% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -97.252% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -15.357% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 51.606% |
| ContraFect Corporation | -65.15 Million USD | 93.431% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 12.404% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -147.763% |
| IMV Inc. | -36.48 Million USD | 88.269% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 46.896% |
| MultiCell Technologies, Inc. | -380.07 USD | -1126008.875% |
| ONE Bio Corp. | 8.67 Million USD | 149.328% |
| Accustem Sciences Inc. | -3.74 Million USD | -14.242% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 91.72% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -237.77% |
| Q BioMed Inc. | -2.05 Million USD | -108.568% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -14.653% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -79.766% |
| Biomind Labs Inc. | -1.21 Million USD | -252.461% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 92.834% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -37.986% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 45.844% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -119.572% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -28479.073% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 73.033% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 26.426% |
| GB Sciences, Inc. | -1.36 Million USD | -214.318% |
| Alpha Cognition Inc. | -13.77 Million USD | 68.924% |
| HST Global, Inc. | -146.21 Thousand USD | -2827.298% |
| CSL Limited | 2.64 Billion USD | 100.162% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -143.907% |
| Halberd Corporation | -79.67 Thousand USD | -5271.758% |
| Enzolytics Inc. | -2.17 Million USD | -96.616% |
| Agentix Corp. | -1.37 Million USD | -211.452% |
| Resverlogix Corp. | -3.61 Million USD | -18.56% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -34.955% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.549% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4467.349% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 161.809% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -7.727% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -41.435% |
| AVAX Technologies, Inc. | -6.41 Million USD | 33.267% |
| Zenith Capital Corp. | -10.59 Million USD | 59.607% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.517% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -18314.947% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -3.234% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6981.335% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -113.454% |
| Kadimastem Ltd | -3.3 Million USD | -29.407% |
| Helix BioMedix, Inc. | -1.05 Million USD | -305.281% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -12.071% |
| BioStem Technologies, Inc. | -8.48 Million USD | 49.546% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -869.711% |
| LadRx Corporation | 400.44 Thousand USD | 1168.817% |
| Cell Source, Inc. | -5.32 Million USD | 19.567% |
| Regen BioPharma, Inc. | 1.02 Million USD | 518.17% |
| Regen BioPharma, Inc. | 1.02 Million USD | 518.17% |
| NovAccess Global Inc. | -4.76 Million USD | 10.257% |
| Affymax, Inc. | -14.42 Million USD | 70.327% |
| Itoco Inc. | -1.86 Million USD | -129.0% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 3.659% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -156.441% |
| Mobile Lads Corp. | -2.26 Million USD | -89.105% |
| CytoDyn Inc. | -49.84 Million USD | 91.413% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -5315.462% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1776.149% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -354.58% |
| SYBLEU INC | -180.3 Thousand USD | -2273.77% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -165.387% |
| International Stem Cell Corporation | -131 Thousand USD | -3167.177% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -7786.207% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -69.154% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 91.097% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -102.46% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -448.095% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -35.101% |
| Neutra Corp. | -233.46 Thousand USD | -1733.252% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 78.907% |
| PureTech Health plc | -65.69 Million USD | 93.485% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 79.874% |
| IXICO plc | -1.17 Million USD | -263.328% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 56.885% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 92.508% |
| CSL Limited | 2.64 Billion USD | 100.162% |
| Cellectis S.A. | -103.17 Million USD | 95.852% |